Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.
The pharmacokinetics of levofloxacin in serum and in skin blister fluid (SBF) was determined for 20 volunteers after a single 500-mg oral dose of levofloxacin. In addition, ex vivo bactericidal activity of SBF against Streptococcus pneumoniae and Staphylococcus aureus was studied. SBF containing levofloxacin and granulocytes killed 5.2 log of Streptococcus pneumoniae bacteria and 2.0 log of Staphylococcus aureus bacteria during a 6-h incubation.
Trampuz
A
A
Division of Infectious Diseases, Departments of Internal Medicine and Research, University Hospitals, Basel, Switzerland.
Wenk
M
M
Rajacic
Z
Z
Zimmerli
W
W
D000890:Anti-Infective Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D001768:Blister / Q000378:metabolism; D001826:Body Fluids / Q000382:microbiology; D006098:Granulocytes / Q000378:metabolism / Q000382:microbiology; D006801:Humans; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000493:pharmacokinetics* / Q000494:pharmacology; D011008:Pneumococcal Infections / Q000378:metabolism*; D017192:Skin Diseases, Bacterial / Q000378:metabolism*; D013203:Staphylococcal Infections / Q000378:metabolism*; D013211:Staphylococcus aureus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D013997:Time Factors
D000890:Anti-Infective Agents; D064704:Levofloxacin; D015242:Ofloxacin